Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observational study evaluating drug–drug interactions between ledipasvir/sofosbuvir and other medications in children and adolescents with hepatitis C virus

Trial Profile

An observational study evaluating drug–drug interactions between ledipasvir/sofosbuvir and other medications in children and adolescents with hepatitis C virus

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary) ; Amlodipine; Amoxicillin; Aspirin; Azathioprine; Betamethasone; Calcium carbonate; Captopril; Cefepime; Chlorphenamine; Ciclosporin; Colchicine; Colecalciferol; Cyclophosphamide; Deferoxamine; Diclofenac; Fludrocortisone; Folic acid; Furosemide; Hydroxycarbamide; Hydroxychloroquine; Insulin; Iron; Leflunomide; Levetiracetam; Levocarnitine; Mesalazine; Methyldopa; Methylprednisolone; Metronidazole; Montelukast; Mycophenolate mofetil; Nitazoxanide; Ondansetron; Pantoprazole; Paracetamol; Penicillins; Piracetam; Prednisolone; Propranolol; Ranitidine; Sertaconazole; Sodium bicarbonate; Sotalol; Spironolactone; Sulfasalazine; Terbutaline; Ursodeoxycholic acid; Warfarin
  • Indications Hepatitis C
  • Focus Adverse reactions

Most Recent Events

  • 04 Jul 2019 New trial record
  • 25 Jun 2019 Results published in the Clinical Drug Investigation

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top